Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
0 hedge funds and large institutions have $0 invested in Longboard Pharmaceuticals, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 124 closing their positions.
100% less funds holding
Funds holding: 125 → 0 (-125)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $1.33B → $0 (-$1.33B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 124
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$145M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$105M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$97M |
| 4 |
BlackRock
New York
|
-$94.6M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$93M |
LBPH Hedge Fund Activity: Q4 2024 in Review
0 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q4 2024, worth a combined $0 — down 100% from $1.33B a quarter earlier.
Sellers outnumbered buyers: 124 funds closed out of LBPH and 0 opened new positions — a net loss of 124 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Fidelity Investments, exiting entirely with an estimated $145M sold.
- 0 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q4 2024, down from 125 in Q3 2024.
- Funds reported $0 of Longboard Pharmaceuticals, Inc. Common Stock stock for Q4 2024, down 100% quarter-over-quarter.
- 0 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q4 2024 and 124 closed out, a net change of -124 holders.
- The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q4 2024 was Fidelity Investments, an estimated $145M sold.
Based on aggregated 13F filings for Q4 2024.